Garry Menzel

(Dr. Garry Menzel Ph.D.)

Currently holds a position at TCR2 Therapeutics Inc

Positions

Position Company Period
President, Chief Executive Officer, Director TCR2 Therapeutics Inc Dec. 1, 2018 -
Chief Executive Officer, Director TCR2 Therapeutics Inc Jan. 1, 2016 - Dec. 1, 2018
Executive Vice President, Chief Business and Strategy Officer Axcella Health Inc Oct. 1, 2015 - Jan. 1, 2018
Chief Financial Officer DaVita Inc Nov. 1, 2013 - March 30, 2015
Chief Operating Officer, Executive Vice President - Finance Regulus Therapeutics Inc Jan. 2, 2009 - June 21, 2013
Garry Menzel's trades of Adaptimmune Therapeutics PLC's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2023-07-10 2023-07-10
S Sale
47,702 -38.9%
0.91
USD 43,447 		47,702 -38.9% 0.91 USD 43,447
2022-12-13 2022-12-13
PS Planned sale
11,000 -7.3%
1.06
USD 11,682 		11,000 -7.3% 1.06 USD 11,682
2022-12-13 2022-12-12
PS Planned sale
10,613 -6.6%
1.10
USD 11,674 		10,613 -6.6% 1.10 USD 11,674
2022-12-13 2022-12-09
PS Planned sale
10,325 -6.0%
1.13
USD 11,678 		10,325 -6.0% 1.13 USD 11,678
2022-12-09 2022-12-08
PS Planned sale
9,314 -5.2%
1.25
USD 11,680 		9,314 -5.2% 1.25 USD 11,680
2022-12-09 2022-12-07
PS Planned sale
9,111 -4.8%
1.28
USD 11,680 		9,111 -4.8% 1.28 USD 11,680
2022-12-07 2022-12-06
PS Planned sale
14,886 -7.3%
1.35
USD 20,081 		14,886 -7.3% 1.35 USD 20,081
2022-12-07 2022-12-05
PS Planned sale
8,530 -4.0%
1.37
USD 11,703 		8,530 -4.0% 1.37 USD 11,703
2022-12-05 2022-12-02
PS Planned sale
8,408 -3.8%
1.39
USD 11,687 		8,408 -3.8% 1.39 USD 11,687
// ... existing code ... // ... rest of the file ...